MARKET

CHRS

CHRS

Coherus Bioscien
NASDAQ
2.110
+0.030
+1.44%
Opening 14:41 05/22 EDT
OPEN
2.090
PREV CLOSE
2.080
HIGH
2.140
LOW
2.080
VOLUME
509.21K
TURNOVER
0
52 WEEK HIGH
5.63
52 WEEK LOW
1.430
MARKET CAP
242.07M
P/E (TTM)
-2.7044
1D
5D
1M
3M
1Y
5Y
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Johnson & Johnson (JNJ), Eli Lilly & Co (LLY) and Coherus Biosciences (CHRS)
TipRanks · 2d ago
Weekly Report: what happened at CHRS last week (0513-0517)?
Weekly Report · 2d ago
Coherus Biosciences (CHRS) Gets a Hold from Maxim Group
Maxim Group analyst Jason McCarthy maintained a Hold rating on Coherus Biosciences (CHRS – Research Report) The company’s shares closed yesterday at $ . McCarthy covers the Healthcare sector and has an average return of and a success rate on recommended stocks. The analyst consensus on coherus bioscienced is a Strong Buy.
TipRanks · 4d ago
Analysts Conflicted on These Healthcare Names: Spero Therapeutics (SPRO) and Coherus Biosciences (CHRS)
TipRanks · 6d ago
Coherus Biosciences: Strong Oncology Focus and Strategic Financial Moves Justify Outperform Rating
TipRanks · 05/14 08:45
Coherus BioSciences Price Target Cut to $7.00/Share From $8.00 by Truist Securities
Dow Jones · 05/13 12:29
Coherus BioSciences Is Maintained at Buy by Truist Securities
Dow Jones · 05/13 12:29
Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7
Benzinga · 05/13 12:19
More
About CHRS
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.

Webull offers Coherus Biosciences Inc stock information, including NASDAQ: CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.